Medical and scientific publisher Informa Healthcare, UK, has compiled the results of recent Impact Factors published by Thomson Reuters. According to results from the 2010 Journal Citation Reports (JCR), the influence from Informa Healthcare journals has grown during the past year.
Informa increased journal Impact Factors for 80 journals targeting niche communities. Improved categorical rankings for these journals coupled with strong performance across rapid-publication titles are said to demonstrate the quality of papers being published.
The Critical Reviews series had significant increases to three titles - Critical Reviews in Microbiology (up 67% to 5.345), Critical Reviews in Biotechnology (up 48% to 5.281), and Critical Reviews in Clinical Laboratory Sciences (up 28% to 5.741). The Expert Opinion series seeks to provide authoritative analysis to support every stage within the pharmaceutical R&D pipeline with key increases to Expert Opinion on Therapeutic Patents (up 88% to 2.412), Expert Opinion on Emerging Drugs (up 36% to 3.284), and Expert Opinion on Drug Delivery (up 34% to 4.482).
Other highlights across the journal portfolio include: Current Medical Research & Opinion (CMRO) increased to 4% to 2.609. Other notable increases included Harvard Review of Psychiatry (up 63% to 2.197), Journal of Maternal Fetal and Neonatal Medicine (up 52% to 2.071), Chronobiology International (up 40% to 5.576), Acta Oncologica (up 38% to 3.137), Cytotherapy (up 33% to 2.925), Free Radical Research (up 27% to 2.805), International Reviews of Immunology (up 23% to 3.239), Drug Metabolism Reviews (up 15% to 6.263), and Amyotrophic Lateral Sclerosis (up 15% to 3.397).
Eight journals also scored their first Impact Factor including COPD: Journal of Chronic Obstructive Pulmonary Disease (2.250), Journal of Cosmetic and Laser Therapy (1.849), Expert Opinion on Drug Discovery (1.495), and International Journal of Speech Language Pathology (1.120).
Search for more Impact factors related information
To access our daily STM news feed through your iPhone, iPad, or other smartphones, please visit www.myscoope.com for a mobile friendly reading experience.
